Ten wounded in Israeli strikes on Gaza
2009-11-22 11:29:46 - Jerusalem, Nov 22 (DPA) At least 10 Palestinians were injured in three successive Israeli airstrikes overnight and early Sunday on the southern, central and northern Gaza Strip, medical officials and the Israeli military said.

Decode your food cravings
2009-11-22 11:27:51 - The urge to scarf is more than a hunger cue gone wild. It's a window into your nutritional needs and your personality.

Lucknow Zoo authorities treating tiger for cancer
2009-11-22 09:31:35 - Lucknow, Nov 22 : Lucknow Zoo authorities, aided by veterinarians, are treating a man-eater tiger diagnosed with cancer.

Akhtar neglected doctor friend's advise on liposuction surgery
2009-11-22 09:31:35 - Islamabad, Nov.22 : Controversial Pakistan pacer Shoaib Akhtar's close doctor friend, Tauseef Razaq, said the fast bowler had always consulted him before any medical treatment, but, didn't heed his advise against going for liposuction surgery.

Abbott To Develop New Heart Failure Test On ARCHITECT® Immunochemistry Diagnostics Platform
2009-11-22 07:58:51 - Abbott (NYSE: ABT) and BG Medicine, Inc. announced a development and commercialization agreement for galectin-3, a novel biomarker that may play a role in detecting the development and progression of heart failure. The assay will be developed for Abbott's ARCHITECT immunochemistry instrument platform, specifically the company's i1000SR and i2000SR instruments.

AstraZeneca Submits US New Drug Application For Brilinta (Ticagrelor), An Investigational Antiplatelet Agent
2009-11-22 07:58:51 - AstraZeneca announced it has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for ticagrelor, an investigational oral antiplatelet treatment for the reduction of major adverse cardiac events in patients with acute coronary syndrome (ACS). The proposed trade name for ticagrelor is BRILINTA, pending approval from the FDA.

European Medical Advisory Committee Does Not Recommend Approval Of Avastin For Deadly Form Of Brain Cancer
2009-11-22 07:58:51 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the Committee for Medicinal Products for Human Use (CHMP), which is responsible for conducting the initial assessment of medicinal products that have been filed for marketing authorisation in Europe, has issued a negative opinion relating to the appro

Sanofi-aventis And Medicines For Malaria Venture To Launch The Largest Ever Study Of An Antimalarial Drug
2009-11-22 07:58:51 - Sanofi-aventis ( EURONEXT: SAN and NYSE: SNY) and Medicines for Malaria Venture (MMV) announced that they have entered an agreement to launch the largest safety and efficacy study of an antimalarial drug. This field-monitoring program on ASAQ, a fixed-dose combination of artesunate and amodiaquine, started in Côte d'Ivoire in October 2009.

Novartis Influenza A(H1N1) 2009 Vaccine US Interim Data Show Lower Doses Of Antigen May Suffice To Generate A Protective Immune Response
2009-11-22 07:58:51 - Novartis announced new interim data from ongoing clinical trials demonstrating that a single 7.5µg dose of the company's influenza A(H1N1) 2009 unadjuvanted vaccine, half of the currently-approved US dose, fulfilled immune response criteria associated with protection in adults and the elderly (=65 years of age). The data also showed a single 3.

Merck KGaA: CHMP Opinion For Erbitux In Advanced Non-Small Cell Lung Cancer
2009-11-22 07:58:51 - The Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMEA), has adopted a negative opinion for the use of Erbitux® (cetuximab) in combination with platinum-based chemotherapy for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing, advanced or metastatic non-small cell lung cancer (NSCLC).

» Archived Health Coverage